FMC Corporation announced that its board has authorized a review of strategic options, including a potential sale, following the release of its fourth‑quarter 2025 earnings on February 4, 2026.
The company reported Q4 revenue of $1.08 billion, a 12% decline from the $1.22 billion earned in the same period a year earlier. The drop was driven by a 6% price reduction on its flagship active ingredient Rynaxypyr® and weaker sales in its India commercial business, which the company is divesting.
Adjusted earnings per share came in at $1.20, falling $0.01 short of the consensus estimate of $1.21. The miss was largely due to the $13.74 million goodwill impairment that reduced GAAP earnings, while operating costs were largely contained, keeping the adjusted EPS close to expectations.
While legacy segments underperformed, new active ingredients such as Isoflex, fluindapyr, Dodhylex, and rimisoxafen generated roughly $200 million in sales in 2025, a 54% year‑over‑year increase, underscoring the company’s shift toward a growth‑portfolio strategy.
Management reiterated its 2026 priorities of debt reduction and portfolio realignment, targeting a $1 billion debt payoff through asset sales and licensing agreements. The company also guided 2026 revenue to $3.60 billion–$3.80 billion, a 5% decline at the midpoint versus 2025, and adjusted EBITDA to $670 million–$730 million, signaling cautious optimism amid near‑term revenue pressure.
CEO Pierre Brondeau said the board’s decision to explore strategic options is intended to maximize shareholder value while the company continues to strengthen its balance sheet and pursue high‑growth active ingredients. Investors reacted negatively to the earnings miss and the sale exploration, reflecting concerns about the company’s short‑term profitability and long‑term strategic direction.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.